FDA approved Dr. Reddy’s ANDA for Lansoprazole delayed-release capsules

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

- Advertisement -

Dr. Reddy’s Laboratories announced that it will be launching Lansoprazole delayed-release capsules (15 mg and 30 mg), a bioequivalent generic version of Prevacid®* Delayed-Release Capsules, in the US market. The Food & Drug Administration (FDA) approved Dr. Reddy’s ANDA for Lansoprazole delayed-release capsules on October 15, 2010. Launch preparations are complete and shipments will commence shortly. Dr. Reddy’s Lansoprazole delayed-release capsules are available in bottles of 30 & 90 counts in 15mg and 90 and 500 counts in 30 mg.

Daiichi Sankyo Enter AI Oncology Collaboration with Tempus

FDA Seeks Input on National Priority Voucher Pilot Program

Merck Acquires Terns Pharmaceuticals in $6.7 Billion Deal

What Hospitals Must Get Right When Scaling Their Provider Networks

Axplora $60M Investment Expands HPAPI Manufacturing Capacity

Integrating high-voltage leak detection into automated visual inspection

Aligning Global Clinical Trials with Standardized Drug Data

Who are the Top Vendors for Budget-Friendly Laboratory Supplies?

Future-proof vial filling – How flexibility Along the Line Defines Success

How Smart Digital Strategies are Leading the Way in Pharmaceutical Manufacturing

Kindeva® commemorates 70 years of pMDI Innovation

CVC Welcomes Apollo as Minority Investor in Syntegon: Partnership to Accelerate…

Syntegon and Lyocontract: Growing Together

Kindeva Appoints Mike Cowhig as Chief Legal Officer

Inizio Ignite Builds its Connected Solution with Key Leadership Appointments

FDA approved Dr. Reddy’s ANDA for Lansoprazole delayed-release capsules

Daiichi Sankyo Enter AI Oncology Collaboration with Tempus

FDA Seeks Input on National Priority Voucher Pilot Program

Merck Acquires Terns Pharmaceuticals in $6.7 Billion Deal

Sustainability and Traceability in Nutraceutical Supply

Daiichi Sankyo Enter AI Oncology Collaboration...

FDA Seeks Input on National Priority...

Merck Acquires Terns Pharmaceuticals in $6.7...

What Hospitals Must Get Right When...

Axplora $60M Investment Expands HPAPI Manufacturing...

Daiichi Sankyo Enter AI Oncology Collaboration with Tempus

FDA Seeks Input on National Priority Voucher Pilot Program

Merck Acquires Terns Pharmaceuticals in $6.7 Billion Deal

What Hospitals Must Get Right When Scaling Their Provider Networks

About us

SUBSCRIBE US

System

RESOURCES

ARCHIVE LINKS

Subscribe

Sustainability and Traceability in Nutraceutical Supply

Daiichi Sankyo Enter AI Oncology Collaboration with Tempus